Effects of Montelukast on Neuroinflammation in Parkinson's Disease: An Open Label Safety and Tolerability Trial with CSF Markers and [ 11 C ] PBR28 PET
Movement Disorders · 2025
DOI: 10.1002/mds.30144 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders, 2025. Verfasst von Johan Wallin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Neurology, Region Stockholm, Stockholm, Sweden. Hauptthemen laut MEDLINE: Cyclopropanes, Sulfides, Parkinson Disease, Quinolines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Axel and Margaret Ax:son Johnson Foundation.
Abstract (Originalsprache)
Background
Dysregulated leukotriene signaling is proposed to be involved in pathogenesis of Parkinson's disease (PD).
Objective
The objective was to examine the safety and tolerability of montelukast, a cysteinyl‐leukotriene receptor1 and GPR17 antagonist, in patients with PD. Secondary outcomes were target engagement, effects on PD signs/symptoms, and central neuroinflammation.
Methods
Fifteen PD patients were recruited to a 12‐week open‐label trial of 20 mg bi‐daily montelukast treatment. Patients underwent ratings with the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS‐UPDRS), the Montreal Cognitive Assessment (MoCA), Beck's Depression Inventory (BDI), Parkinson's Disease Questionnaire‐39 (PDQ‐39), [ 11 C]PBR28‐PET, and lumbar punctures before and during montelukast treatment.
Results
All patients completed the study. Three patients reported loose stool. No serious adverse events related to treatment were reported. MDS‐UPDRS‐Total scores improved by 6.9 points. Very low levels of montelukast were detected in all cerebrospinal fluid (CSF) samples and resulted in a reduction in inflammation/metabolism markers. [ 11 C]PBR28 binding was lowered in high, but not mixed, affinity binders after montelukast.
Conclusions
Montelukast crosses the blood–brain barrier at very low levels and is well tolerated and safe in PD patients. Preliminary effects on neuroinflammation and clinical scores motivate a future randomized controlled trial (RCT) in PD. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Neurology, Region Stockholm, Stockholm, Sweden.
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
- Centre for Psychiatry Research, Karolinska Institutet, Stockholm, Sweden.
ORCID-Profile: Johan Wallin, Anton Forsberg, Per Svenningsson
Förderung
- Axel and Margaret Ax:son Johnson Foundation
Zitieren
APA
Wallin, J., Forsberg, A., & Svenningsson, P. (2025). Effects of Montelukast on Neuroinflammation in Parkinson's Disease: An Open Label Safety and Tolerability Trial with CSF Markers and [ 11 C ] PBR28 PET. Movement Disorders. https://doi.org/10.1002/mds.30144
Vancouver
Wallin J, Forsberg A, Svenningsson P. Effects of Montelukast on Neuroinflammation in Parkinson's Disease: An Open Label Safety and Tolerability Trial with CSF Markers and [ 11 C ] PBR28 PET. Movement Disorders. 2025. doi:10.1002/mds.30144
BibTeX
@article{Wallin2025,
author = {Wallin, Johan and Forsberg, Anton and Svenningsson, Per},
title = {Effects of Montelukast on Neuroinflammation in Parkinson's Disease: An Open Label Safety and Tolerability Trial with CSF Markers and [ 11 C ] PBR28 PET},
journal = {Movement Disorders},
year = {2025},
doi = {10.1002/mds.30144}
}
EUVIMED